Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) is projected to issue its Q4 24/25 quarterly earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of $0.20 per share and revenue of $83.70 billion for the quarter.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, analysts expect Dr. Reddy's Laboratories to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Dr. Reddy's Laboratories Trading Up 1.2 %
Dr. Reddy's Laboratories stock opened at $13.95 on Tuesday. The firm's 50-day moving average is $13.18 and its 200-day moving average is $14.19. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. Dr. Reddy's Laboratories has a 1 year low of $12.26 and a 1 year high of $16.89. The company has a market cap of $11.65 billion, a P/E ratio of 22.21 and a beta of 0.51.
Dr. Reddy's Laboratories Company Profile
(
Get Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
